REPL News and Press, Replimune Group Inc. From 10/20/25

2025-10-20 12:41:14 ET DENVER, Colo., Oct 20, 2025 ( 247marketnews.com )- Wall Street is dialing into a mix of bold biotech breakthroughs, AI-powered real estate finance, and a Live Music Innovator that could redraw the sentertainment map. Here’s what’s driving the action ...

2025-10-20 11:07:56 ET from Wedbush issued a price target of $18.00 for REPL on 2025-10-20 13:05:35. The adjusted price target was set to $18.00. At the time of the announcement, REPL was trading at $9.15. The overall price target consensus is at $25.50 with high price o...

A look at the top 10 most actives in the United States Beyond Meat Inc. (BYND) rose 46.2% to $0.9441 on volume of 248,997,232 shares Adaptimmune Therapeutics plc (ADAP) fell 70.1% to $0.0598 on volume of 138,511,757 shares Replimune Group Inc. (REPL) rose 101.3% to $9.06 on volume of 63,729...

2025-10-20 09:39:00 ET DENVER, Colo., Oct 20, 2025 ( 247marketnews.com )- Wall Street is opening the week with a spotlight on experiential entertainment, oncology breakthroughs, and biopharma advancements, and other tickers are hitting high notes. Live entertainment operator VENU ...

2025-10-20 09:00:49 ET More on Replimune Group Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating Replimune Group: The Prospects For FDA Approval After Rejection Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Replimune c...

WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biolog...

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was pre...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July...

2025-09-20 09:21:41 ET The last time I spoke about Replimune ( REPL ) it was with respect to a Seeking Alpha article entitled " Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma . " With respect to this article, I noted the company's opportunity t...

2025-09-19 11:17:20 ET More on Replimune Group Replimune Group: The Prospects For FDA Approval After Rejection Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Replimune down amid uncertainty over accelerated approval Replimune gains as FDA...